Veru Inc
Veru Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for women's health and urology.
Business. Veru Inc (VERU.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As specific segment and geographic data are not provided, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-11-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Veru Inc (VERU.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As specific segment and geographic data are not provided, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
Veru Inc has a market capitalization of $33.55 million and a price-to-book ratio of 0.74, indicating that the company is trading at a discount to its book value. The company's liquidity position is strong, with a current ratio of 4.72 and $34.74 million in cash and equivalents, which provides a buffer against short-term obligations. The debt-to-equity ratio of 0.22 suggests a conservative capital structure with limited leverage.
The company's profitability metrics are negative, with a return on equity of -22.18% and a return on assets of -13.96%, indicating that it is not generating returns for shareholders or effectively utilizing its assets. The operating and net losses of $8.89 million and $10.03 million, respectively, highlight the company's ongoing financial challenges. These results are below the industry norms for profitability and returns, which typically require positive ROE and ROA figures for long-term sustainability.
Veru Inc's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the company's risk profile from a segment or regional perspective. The absence of detailed segment reporting limits the ability to evaluate the performance of different product lines or geographic regions.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The negative operating and free cash flows of $11.67 million and $8.68 million, respectively, indicate that the company is not generating sufficient cash to fund operations or expansion. The capital expenditure of $40,660 is minimal, suggesting limited investment in long-term growth initiatives.
The risk assessment for Veru Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's strong cash position and low debt levels reduce the likelihood of near-term financial distress. However, the ongoing net losses and negative cash flows pose long-term sustainability risks that could necessitate future equity or debt financing.
Recent events and filings for Veru Inc do not provide specific details on recent developments, but the company's financial performance and analyst estimates suggest a mixed outlook. The mean price target of $24.50 and a strong buy recommendation from analysts indicate some optimism about the company's future. However, the current financial metrics and operational performance suggest that significant improvements are needed to justify such high price targets.
- Veru Inc is trading at a significant discount to its book value, with a price-to-book ratio of 0.74.
- The company has a strong liquidity position, with a current ratio of 4.72 and $34.74 million in cash and equivalents.
- Veru Inc is experiencing negative profitability, with a return on equity of -22.18% and a return on assets of -13.96%.
- Analysts have a generally positive outlook, with a mean price target of $24.50 and a strong buy recommendation.
- The company's financial performance and operational metrics suggest a need for significant improvements to justify the high price targets.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income −234,0% YoY; Net income +40,4% YoY.
- ▍Operating income −234,0% YoY
- ▍Net income +40,4% YoY
- ▍Free cash flow −203,8% YoY
Operating income +112,5% YoY; Net income +117,0% YoY.
- ▍Operating income +112,5% YoY
- ▍Net income +117,0% YoY
- ▍Free cash flow +115,6% YoY
Operating income +28,4% YoY; Net income +33,1% YoY.
- ▍Operating income +28,4% YoY
- ▍Net income +33,1% YoY
- ▍Free cash flow +29,4% YoY
Operating income +8,6% YoY; Net income +21,2% YoY.
- ▍Operating income +8,6% YoY
- ▍Net income +21,2% YoY
- ▍Free cash flow +9,8% YoY
Operating income -$1.6M.
- ▍Operating income -$1.6M
Operating income -$9.3M.
- ▍Operating income -$9.3M
Operating income -$10.5M.
- ▍Operating income -$10.5M
Operating income -$8.9M.
- ▍Operating income -$8.9M
Operating income +55,4% YoY; Net income +39,9% YoY.
- ▍Operating income +55,4% YoY
- ▍Net income +39,9% YoY
- ▍Free cash flow +55,8% YoY
Operating income +61,4% YoY; Net income +59,4% YoY.
- ▍Operating income +61,4% YoY
- ▍Net income +59,4% YoY
- ▍Free cash flow +62,4% YoY
Revenue $16.3M, −58,6% YoY; Operating income −12,3% YoY.
- ▍Revenue $16.3M, −58,6% YoY
- ▍Operating income −12,3% YoY
- ▍Net income −10,8% YoY
- ▍Free cash flow −10,6% YoY
- ▍Net margin -571.6%
Revenue $39.4M, −35,8% YoY; Operating income −743,6% YoY.
- ▍Revenue $39.4M, −35,8% YoY
- ▍Operating income −743,6% YoY
- ▍Net income −1 236,5% YoY
- ▍Free cash flow −1 269,8% YoY
- ▍Net margin -213.5%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,20 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -29,4M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Admin Officer and CFO · Common Stock Option → Common StockAcquired 164 000 @ $2,25grant · 2026-05-04
- Director, President and CEO · Common Stock Option → Common StockAcquired 604 000 @ $2,25grant · 2026-05-04
- Director · Common Stock Option → Common StockAcquired 104 000 @ $2,25grant · 2026-05-04
- Chief Scientific Officer · Common Stock Option → Common StockAcquired 160 000 @ $2,25grant · 2026-05-04
- Director, Chief Corporate Officer · Common Stock Option → Common StockAcquired 160 000 @ $2,25grant · 2026-05-04
- Director · Common Stock Option → Common StockAcquired 100 000 @ $2,25grant · 2026-05-04
- Director · Common Stock Option → Common StockAcquired 97 000 @ $2,25grant · 2026-05-04
- Director · Common Stock Option → Common StockAcquired 102 000 @ $2,25grant · 2026-05-04
- Chief Admin Officer and CFO · Common Stock Option → Common StockAcquired 27 000 @ $2,49grant · 2025-12-05
- Chief Scientific Officer · Common Stock Option → Common StockAcquired 27 000 @ $2,49grant · 2025-12-05
- Director · Common Stock Option → Common StockAcquired 3 000 @ $2,49grant · 2025-12-05
- Director · Common Stock Option → Common StockAcquired 6 000 @ $2,49grant · 2025-12-05
- Director, President and CEO · Common Stock Option → Common StockAcquired 100 000 @ $2,49grant · 2025-12-05
- Director · Common Stock Option → Common StockAcquired 6 000 @ $2,49grant · 2025-12-05
- Director · Common Stock Option → Common StockAcquired 4 000 @ $2,49grant · 2025-12-05
- Director, Chief Corporate Officer · Common Stock Option → Common StockAcquired 27 000 @ $2,49grant · 2025-12-05
- Director · Common Stock Option → Common StockAcquired 6 000 @ $3,89grant · 2025-10-01
- Director · Common Stock Option → Common StockAcquired 3 000 @ $3,89grant · 2025-10-01
- Director · Common Stock Option → Common StockAcquired 7 000 @ $3,89grant · 2025-10-01
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Veru Inc Market data — financials · 2026-05-29
- Veru Inc Market data — analyst estimates · 2026-05-29
- Veru Inc Market data — ESG · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$6M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): 0.28xDerived (calculated)
- Current ratio (FY 2025-12-31): 5.16xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 24.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 39.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 19.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -20.9%Derived (calculated)
- Shareholders' equity (annual): USD 37.12MSEC XBRL filing
- Shares outstanding (annual): 16.05MSEC XBRL filing
- Current assets (annual): USD 36.81MSEC XBRL filing
- Total liabilities (annual): USD 10.44MSEC XBRL filing
- Total assets (annual): USD 47.57MSEC XBRL filing
- Current liabilities (annual): USD 7.13MSEC XBRL filing
- Cash & equivalents (annual): USD 32.99MSEC XBRL filing
- Operating cash flow (YoY) (2025-09-30 vs 2024-09-30): -38.6%Derived (calculated)
- Net income (YoY) (2025-09-30 vs 2024-09-30): 39.9%Derived (calculated)
- Capex (YoY) (2025-09-30 vs 2024-09-30): -99.3%Derived (calculated)
- EPS (basic) (YoY) (2025-09-30 vs 2024-09-30): 44.6%Derived (calculated)
- R&D expense (YoY) (2025-09-30 vs 2024-09-30): 22.0%Derived (calculated)
- Operating income (YoY) (2025-09-30 vs 2024-09-30): 31.6%Derived (calculated)
- Capex (annual): USD 1.08KSEC XBRL filing
- Operating cash flow (annual): USD -30.04MSEC XBRL filing
- R&D expense (annual): USD 15.59MSEC XBRL filing
- Net income (annual): USD -22.73MSEC XBRL filing
- Total operating expenses (annual): USD 35.53MSEC XBRL filing